This 30-minute self-study lecture is intended for radiologists, radiologic technologists, neurologists, pediatricians, and other physicians who refer patients for MRI exams.
|0.5 AMA PRA Category 1
|0.5 ARRT Category A+ credit
|Estimated time to complete this activity is 40 minutes
Click to register for this course
The use of gadolinium-based contrast agents in MR imaging has been well-established for 25 years and is an extremely valuable tool for visualizing areas of interest.
However, recent publications have shown hyperintensities on MRI in the dentate nucleus and globus pallidus of patients who have received multiple gadolinium-based contrast injections and have no severe renal insufficiency. Gadolinium deposits have histopathologically been confirmed in the brain tissue of patients exhibiting these hyperintensities. While further research is needed to evaluate the clinical significance of these findings, radiologists, radiologic technologists, and referring physicians must be aware of the potential implications for ordering and performing contrast-enhanced MRI, especially in those patients who may require multiple scans.
At the conclusion of this activity, participants should be better able to:
- Explain the classification of GBCAs and clinical relevance of their molecular structures and other physicochemical properties and how these affect patient safety
- Discuss recent studies reporting hyperintensity in the dentate nucleus and globus pallidus on MRI and histopathologically confirmed gadolinium deposits in patients who have undergone multiple contrast-enhanced MRI scans
- Discuss the association of GBCA classification with hyperintensities and gadolinium deposits found in the brain
- Implement the current FDA, ACR, and EMA guidelines for GBCA usage
Accreditation & Credit
ACCME Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and International Center for Postgraduate Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
SA-CME: This activity meets the criteria for self-assessment toward the purpose of fulfilling requirements in the American Board of Radiology (ABR) Maintenance of Certification Program.
The European Accreditation Council for CME (EACCME®): The UEMS-EACCME® has mutual recognition agreements with the American Medical Association (AMA) for live events and e-learning materials. For more information, go to http://www.uems.eu/uems-activities/accreditation/eaccme.
This program has been approved by the American Society of Radiologic Technologists (ASRT) for 0.5 hour of ARRT Category A+ continuing education credit.
ICPME accepts American Express, Discover, MasterCard, and Visa. Please note: tuition payments are non-refundable.
Tuition for this course includes:
- Unlimited access to the course
- Certificate of Credit
How to Enroll and Participate
- Click ENROLL NOW and follow the registration and payment instructions
- Click the blue link to view the course.
How to Receive Credit
- Login to your account at www.icpme.us
- Listen to the entire online presentation.
- From your ICPME account, click on MY ACCOUNT, and click on the Course.
- On the Course page, click the buttons for POSTTEST and for EVALUATION.
- A passing grade of at least 75% is required to receive credit. You may take the test up to three times.
- Upon receipt of a passing grade, you will be able to print and/or save a certificate of credit from your account at www.icpme.us.
Kohkan Shamsi, MD, PhD
Co-Founder, The Blinded Reader and Investigator Training Institute (BRITI)
New York, NY
Kohkan Shamsi, MD, PhD, co-founder and principal of BRITI/RadMD, is a radiologist with over 20 years of clinical development experience in the pharmaceutical industry.
He has executed and supervised clinical development programs and regulatory submissions for 13 MRI and CT contrast agents and radiopharmaceuticals that led to 7 regulatory approvals in the USA, Europe, Japan, and other countries.
Dr. Shamsi has authored a book and book chapters and published more than 90 full publications and abstracts in indexed journals. Dr. Shamsi participates regularly in various scientific forums, meetings, and initiatives for image standardization, image evaluations, and image management for drug development. He is regularly invited to chair/speak at national and international scientific meetings.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
The faculty has reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Kohkan Shamsi, MD, PhD works as a consultant for Guerbet Group.
The following planners and managers have reported NO financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Trace Hutchison, PharmD
Samantha Mattiucci, PharmD, CCMEP
Linda McLean, MS
Victoria Phoenix, BS
Jan Schultz, RN, MSN, CCMEP
Judi Smelker-Mitchek, RN, BSN
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
For questions regarding this program, please contact ICPME:
Phone: 607-257-5860 X10
JOINTLY PROVIDED BY
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
©2015 ICPME. All rights reserved.